Teva drops patent case against Lilly after two Ajovy patents deemed invalid

It’s the end of the road for one of Teva’s patent lawsuits against migraine competitor Eli Lilly.

After filing the case in 2021, a patent trial and appeal board has since found two of Teva’s Ajovy patents invalid based on earlier publications that already disclosed the methods for treating migraines with antibodies. With that, the companies agreed to dismiss the patent case, according to the dismissal filing in Massachusetts federal court.